Moleculera Labs is based at the University of Oklahoma (OU) Research Park in Oklahoma City, and is the only clinical laboratory performing the Cunningham Panel™. Moleculera Labs is accredited by CLIA (Clinical Laboratory Improvement Amendment) and COLA (Commission on Laboratory Accreditation) and licensed to accept physician’s orders from 49 states.

The Cunningham Panel™ was developed based on years of research conducted by Dr. Madeleine Cunningham at the University of Oklahoma in conjunction with Dr. Susan Swedo at the National Institutes of Mental Health (NIMH). The collective result of this panel was developed to assist physicians in their diagnosis of Neuropsychiatric Disorders, and support an appropriate treatment decision.

Laboratory Testing Overview

When the clinical diagnosis of Neuropsychiatric Disorders is made or suspected, the clinician can turn to the results of a patient’s Cunningham Panel™ for objective laboratory evidence to support their clinical diagnosis.

Cunningham Panel Overview

The Cunningham Panel™ can help identify the level of autoimmune antibodies associated with Neuropsychiatric Disorders and the capability they have to stimulate and trigger neurologic behavior.
Cunningham Panel Measures

Cunningham Panel Measures

The Cunningham Panel™ is comprised of five (5) different tests. Four of these clinical tests include enzyme-linked immunosorbent assays (ELISAs) to measure antibody titers against four neuronal antigens present in the brain.
Cunningham Sensitivity and Specificity

Cunningham Panel™ Sensitivity and Specificity

Several published studies demonstrate the sensitivity (rate of true positives), specificity (rate of true negatives), and accuracy of the Cunningham Panel™.
Cunningham Panel Results and Symptom Correlation

Cunningham Panel™ Results and Symptom Correlation

Autoantibodies against the neuronal targets measured by the Cunningham Panel™ were selected based upon their biological association with specific neurologic and psychiatric symptoms.
Ordering Lab Tests for Neuropsychiatric Disorders

Ordering Lab Tests

The Cunningham Panel™ of tests requires a physician order before we can receive and process any specimen. We have a secure Prescriber Portal for prescribers to place an order and to review the test results.


Moleculera Labs has designed brochures for both physicians and parents to assist in making a Neuropsychiatric Disorder diagnosis or a PANS/PANDAS diagnosis as well as a brochure answering frequently asked questions about insurance coverage for The Cunningham Panel™. To download these brochures, please click on the brochure you are interested in below.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.